Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ, Kumarakulasinghe NB, Muthu V, Lee M, Walsh R, Low JL, Choo J, Tan HL, Chong WQ, Ang Y, Chan G, Yong WP, Huang Y, Ngoi N, Wong A. Zhao JJ, et al. Among authors: ang y. Oncology. 2021;99(3):192-202. doi: 10.1159/000512000. Epub 2021 Jan 13. Oncology. 2021. PMID: 33440374
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Nickles E, Dharmadhikari B, Yating L, Walsh RJ, Koh LP, Poon M, Tan LK, Wang LZ, Ang Y, Asokumaran Y, Chong WQ, Huang Y, Loh KS, Tay J, Soo R, Koh M, Ho LP, Chan M, Niam M, Soh M, Luah YH, Lim CM, Kaliaperumal N, Au VB, Talib NBSN, Sng R, Connolly JE, Goh BC, Schwarz H. Nickles E, et al. Among authors: ang y. Cancer Immunol Immunother. 2022 Jun;71(6):1531-1543. doi: 10.1007/s00262-021-03075-3. Epub 2021 Oct 18. Cancer Immunol Immunother. 2022. PMID: 34661709 Free PMC article. Clinical Trial.
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
Yadav K, Lim J, Choo J, Ow SGW, Wong A, Lee M, Chan CW, Hartman M, Lim SE, Ngoi N, Tang SW, Ang Y, Chan G, Chong WQ, Tan HL, Tan SH, Goh BC, Lee SC. Yadav K, et al. Among authors: ang y. Breast Cancer Res Treat. 2022 Feb;192(1):131-142. doi: 10.1007/s10549-021-06470-7. Epub 2021 Dec 20. Breast Cancer Res Treat. 2022. PMID: 34928481 Free PMC article. Clinical Trial.
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. Zhu VW, et al. J Thorac Oncol. 2020 Sep;15(9):1484-1496. doi: 10.1016/j.jtho.2020.04.019. Epub 2020 Apr 28. J Thorac Oncol. 2020. PMID: 32360579 Free article.
400 results